The Emirates Drug Establishment (EDE) has signed a memorandum of understanding (MoU) with Novo Nordisk, the global healthcare company known for its treatments for diabetes, obesity and rare diseases, to strengthen cooperation in pharmaceutical manufacturing through advanced technologies.
Novo Nordisk, a global pharmaceutical company and a leader in developing treatments for diabetes, obesity and rare diseases, has announced the establishment of a regional distribution centre in the UAE, further reinforcing the country’s position as a global hub for pharmaceutical manufacturing and advanced supply chains.
Novo Nordisk has announced positive topline results from Pioneer Teens, a phase 3a trial evaluating oral semaglutide for type 2 diabetes in children and adolescents aged 10–17 years.
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events.
